Apsis Aerocom has secured a confirmed work order valued at Rs 4.296867 crore from a local customer in the Healthcare segment.

WHAT HAPPENED

The company received a significant order for Rs 4.296867 crore on September 15, 2026. The awarding entity is a domestic client in the Healthcare sector, though the specific name remains undisclosed due to confidentiality clauses. The contract terms are "as per the customer specification," with an execution timeline of within 7 months.

ORDER IN FINANCIAL CONTEXT

This confirmed order represents a new revenue stream in the Healthcare segment, distinct from the company's recent Aerospace and Defence wins. Since the Trailing Twelve-Month (TTM) revenue stands at Rs 0.0 Cr, standard book-to-bill ratios cannot be computed. The total disclosed order book sums exactly the same last 3 fiscal quarters shown in the order track record table below (sum of the 4 orders disclosed across the last 3 fiscal quarters shown in the table below). This recent inflow activity suggests the company is actively converting pipeline opportunities into executable contracts, even as historical revenue data remains minimal.

COMPANY ORDER TRACK RECORD

Order inflow velocity appears stable, with the majority of recent activity concentrated in Q1FY27. The current order value of Rs 4.296867 crore is consistent with the mid-range of the company's typical per-order size visible in the history, which ranges from Rs 1.1 crore to Rs 7.24 crore.

EXECUTION AND REVENUE QUALITY

The company's consolidated financials for the trailing twelve months show Rs 0.0 Cr in revenue, net profit, and operating profit. This indicates that while orders are being booked, they have not yet translated into recognized revenue in the latest reported period, or the reporting lag has resulted in zero recognition for this window. Future quarterly results will show the conversion of these backlogs into top-line growth.

WORKING CAPITAL AND EXECUTION CAPACITY

Balance sheet and cashflow data are not available in the provided inputs to assess liquidity ratios such as Current Ratio or Total Liabilities/Equity. Consequently, the company's ability to fund working capital for this new Rs 4.296867 crore order without straining resources cannot be evaluated from the current dataset. Operating cashflow figures are also unavailable, preventing an assessment of whether past backlogs are converting to cash efficiently.

WHAT TO WATCH

• Execution timeline: The 7-month delivery window requires efficient project management to ensure timely revenue recognition.
• Segment diversification: Monitor if the Healthcare segment gains traction relative to the dominant Aerospace and Defence portfolio.
• Revenue conversion: Watch for the translation of the Rs 11.93 crore Q1FY27 backlog into actual revenue in upcoming quarterly filings.
• Margin quality: As execution begins, observe the Operating Profit Margin (OPM) on these new contracts compared to any historical benchmarks.

KEY OBSERVATIONS

• Segment expansion: The company has diversified beyond Aerospace and Defence into the Healthcare segment with this confirmed order.
• Zero TTM Revenue: Trailing twelve-month revenue is Rs 0.0 Cr, indicating early-stage commercial operations or significant reporting lags in revenue recognition.
• Order Size Consistency: The new order value aligns with the company's recent average deal size, suggesting stable market positioning rather than a shift to mega-contracts.

Promoter Vinod Kumar Mariyappan confirmed that no new encumbrances were created on his shares or those held by Persons Acting in Concert (PAC) during the financial year ended March 31, 2026. This declaration ensures transparency regarding the shareholding status of the promoter and PACs. The disclosure was submitted to the National Stock Exchange of India Limited in accordance with regulatory requirements.

The submission was made under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation mandates the disclosure of any encumbrance on shares held by promoters or PACs to maintain transparency for shareholders. Mariyappan confirmed that neither he nor the PACs have made any direct or indirect encumbrances other than those previously disclosed.

The following table summarizes the key details of the disclosure:

The letter addressed to the Audit Committee of Apsis Aerocom Limited serves as a formal declaration for the company's records and regulatory compliance. The submission was dated April 6, 2026.